Skip to main content
. 2019 Oct 14;11(10):1550. doi: 10.3390/cancers11101550

Figure 2.

Figure 2

Figure 2

Spironolactone sensitizes cancer cells to anticancer reagents. Cells were treated with the indicated chemotherapeutic reagents (GEM, gemcitabine, 0.1 µM; OSI, osimertinib, 2 µM) in the absence or presence of 25 µM spironolactone (SPL) for three days, and the numbers of viable and dead cells (left panels) as well as the percentage of dead cells (right panels) were then assessed. Values represent the means ± SD of triplicate samples of a representative experiment repeated with similar results. * p < 0.05.